AAML18P1: Stopping Tyrosine Kinase Inhibitors (TKI) to Assess Treatment-Free Remission (TFR) in Pediatric Chronic Myeloid Leukemia - Chronic Phase (CML-CP)

Are you eligible to participate in this study?

You may be eligible for this study if you meet the following criteria:

  • Conditions:
    Chronic Myeloid Leukemia
  • Age: Between 1 - 24 Years
  • Gender: Male or Female
  • Other Inclusion Criteria:
    1) Patient must have histologic verification of CML- Chronic Phase (CP) at original diagnosis. 2) Patient must be in molecular remission with at least a MR4 (< 0.01% BCR-ABL1 (International Scale [IS]) level by real-time quantitative-polymerase chain reaction [RQ-PCR]) for >= 2 consecutive years at the time of enrollment. 3) Patient must have been diagnosed with CML-CP at < 18 years of age.

You may not be eligible for this study if the following are true:

  • 1) Known T3151 mutation •Additional clonal chromosomal abnormalities in Philadelphia chromosome (Ph) positive (+) cells at any time prior to enrollment that include "major route" abnormalities (second Ph, trisomy 8, isochromosome 17q, trisomy 19), complex karyotype or abnormalities of 3q26.2. 2) History of accelerated phase or blast crisis CML. 3) Female patients who are pregnant. 4) Lactating females are not eligible unless they have agreed not to breastfeed their infants and female patients of childbearing potential are not eligible unless a negative pregnancy test result has been obtained.

If you are registered as a volunteer, please log in to contact the study team/express interest in this study.